OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/18/2026
Back to search
Official data from USPTO
MEDINCELL.
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
06/19/2026
Trademark type
Combined
Nice classes
5, 9, 42
Filing date
10/17/2024
Registration date
06/16/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/16/2026
Last transaction
06/19/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
FR
Examiner
KELLY, JOHN M
Law office
N10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
MedinCell S.A.
Representatives
Jonathan M. Gelchinsky Pierce Atwood LLP
Technical classification
Nice Classes
Class 5Class 9Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; veterinary preparations and substances for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratorydiseases and disordersfor the treatment of substance abuse related diseases and disorders; pharmaceutical compositions for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratorydiseases and disordersfor the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; carriers for pharmaceutical and veterinary preparations being drug delivery agents in the form of dissolvable filmscoatings for tablets that facilitate the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; bacteriological culture or cell culture mediums for pharmaceutical and veterinary preparations being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary preparations and substances for subcutaneous delivery for use in contraceptionfor the treatment of schizophreniabipolar disorderbipolar depressionmajor depressive disordersfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders
Class 9
Scientific apparatus and instrumentstools for injecting and administering liquid formulations into testing equipment or other drug delivery devices; laboratory apparatus and instruments for extracting excipients or active pharmaceutical ingredients from in situ forming depotsnot for medical purposes; apparatus and instruments for chemical analysisplatesglass slides or chips having multi-well arrays that can be used in chemical analysis; apparatus and instruments for measuringtesting and analysing chemical compositions; apparatus for analysing gases; weighing apparatus and instruments; measuring apparatus and instrumentsflow controllers; recorded or downloadable computer software for the quantitative long-term monitoring of the release pharmaceutical ingredients into a patient's body; computer hardware
Class 42
Laboratory researchtesting and research laboratory analysis services in the field of drug delivery; laboratory servicesmedical research laboratories; chemical analysis; medicalscientific and industrial research in the field of long-acting injectable compositions and providing information relating thereto; pharmaceutical drug development services; pharmaceutical research and development services; rental of laboratory apparatus and instruments; design and development of laboratory and diagnostic apparatus; development and testing of algorithms and software; consultancy in the field of pharmaceutical research and development; services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticalschemical analysis and clinical trials; providing scientific research information; scientific research in the fields of medicinepharmacology and veterinary medicine
Publications
History of USPTO decisions and trademark events.
29 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/16/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
06/16/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/01/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/31/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/28/2026
PUBO
PUBLISHED FOR OPPOSITION
04/28/2026
GPNX
NOTIFICATION PROCESSED BY IB
04/23/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/22/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/08/2026
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/08/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/28/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/27/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/27/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/27/2026
RFNT
REFUSAL PROCESSED BY IB
11/15/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/29/2025
RFRR
REFUSAL PROCESSED BY MPU
10/29/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/02/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/02/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/02/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/02/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/02/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/11/2025
CNRT
NON-FINAL ACTION WRITTEN
09/10/2025
DOCK
ASSIGNED TO EXAMINER
09/06/2025
MAFR
APPLICATION FILING RECEIPT MAILED
09/05/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/05/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/02/2025
Continuous trademark protection
Get notified about every new filing that threatens MEDINCELL. or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.